# LABT (Lakewood-amedex Biotherapeutics Inc.) - SEC EDGAR Financial Statements

> Lakewood-amedex Biotherapeutics Inc. reported $3.60M in total assets through September 30, 2026 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/LABT
- Markdown: https://convexityos.com/fundamentals/LABT.md
- SEC CIK: 0002079272
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:14 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002079272&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2026 | -- | Sep 30, 2026 |
| Operating Income | FY 2026 | -- | Operating profit |
| Net Income | FY 2026 | -- | GAAP bottom line |
| Diluted EPS | FY 2026 | -- | Split-adjusted |
| Free Cash Flow | FY 2026 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $3.32M | Total debt: $71K |

## Income Statement

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Cost of Revenue | -- | -- | $507K | -- | -- | -- |
| Research & Development | $733K | $503K | $182K | $753K | $147K | $170K |
| Total Operating Expenses | $1.51M | $3.79M | $887K | $1.88M | $637K | $543K |
| **Operating Income** | -$1.51M | -$3.79M | -$887K | -$1.88M | -$637K | -$543K |
| **EBITDA** | -$1.51M | -$3.79M | -$886K | -$1.88M | -$636K | -$541K |
| Interest Income | $36K | $28K | $1.1K | $11K | $5.4K | $4.3K |
| Interest Expense | $0 | $11K | $38K | $38K | $24K | $1.3K |
| **Net Income** | -$1.47M | -$3.77M | -$923K | -$1.91M | -$656K | -$540K |
| Basic EPS | -$0.62 | -$2.75 | -$0.20 | -$3.46 | -$1.66 | -$0.15 |
| **Diluted EPS** | -$0.62 | -$2.75 | -$0.20 | -$3.46 | -$1.66 | -$0.15 |
| Basic Shares Outstanding | 2.4M | 1.4M | 7.0M | 696.9K | 694.5K | 6.9M |
| Diluted Shares Outstanding | 2.4M | 1.4M | 7.0M | 696.9K | 694.5K | 6.9M |

## Balance Sheet

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $2.82M | $2.58M | $12K | $236K |
| Short-Term Investments | $500K | $2.00M | -- | -- |
| **Cash & Short-Term Investments** | $3.32M | $4.58M | $12K | $236K |
| **Total Current Assets** | $3.51M | $4.85M | $51K | $305K |
| Property, Plant & Equipment, Net | $5.7K | $6.9K | $8.1K | $9.2K |
| Other Non-Current Assets | $7.8K | $7.8K | $8.1K | $8.1K |
| **Total Non-Current Assets** | $84K | $115K | $146K | $176K |
| **Total Assets** | $3.60M | $4.96M | $196K | $482K |
| Accounts Payable | $240K | $166K | $548K | $381K |
| **Total Current Liabilities** | $673K | $629K | $3.03M | $2.41M |
| **Total Non-Current Liabilities** | $0 | $0 | $10K | $41K |
| **Total Liabilities** | $673K | $629K | $3.04M | $2.45M |
| **Total Debt (incl. Leases)** | $71K | $102K | $131K | $160K |
| Common Stock | $366 | $217 | $704 | $70 |
| Retained Earnings | -$70.11M | -$68.64M | -$54.27M | -$53.35M |
| **Total Stockholders' Equity** | $2.93M | $4.33M | -$2.84M | -$1.96M |
| Total Equity | $2.93M | $4.33M | -$2.84M | -$1.96M |

## Cash Flow Statement

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$1.47M | -$3.77M | -$923K | -$1.91M | -$656K | -$540K |
| Depreciation & Amortization | $1.2K | $1.2K | $1.2K | $1.2K | $1.2K | $1.2K |
| Stock-Based Compensation | $69K | $61K | $46K | $1.20M | $49K | $54K |
| Change in Payables | $74K | -$382K | $167K | $199K | -$131K | $44K |
| **Operating Cash Flow** | -$1.26M | -$2.10M | -$350K | -$610K | -$509K | -$404K |
| **Financing Cash Flow** | $0 | $6.68M | $125K | $0 | $1.30M | $200K |
| **Net Change in Cash** | $239K | $2.57M | -$225K | -$610K | $791K | -$204K |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Current Ratio | 5.22x | 7.70x | 0.02x | -- | -- | -- |
| Quick Ratio | 4.94x | 7.29x | 0.00x | -- | -- | -- |
| Debt to Equity | 0.02x | 0.02x | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
